MedTrace Logo

Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female

NCT04407078 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-01-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female who are reversed with sugammadex or neostigmine.

Conditions

  • Gallbladder Diseases

Interventions

DRUG

Sugammadex Injectable Product

Sugammadex of 2 mg/kg is injected.

DRUG

Neostigmine Injectable Product

Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.

Sponsors & Collaborators

  • Ajou University School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2021-01-06
Completion
2021-01-06

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407078 on ClinicalTrials.gov